Associations of aspirin, statins and metformin with lung cancer risk and related mortality Source: Breathe, 17 (2) 200325; 10.1183/20734735.0325-2020 Year: 2021
30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator? Source: ERJ Open Res, 4 (4) 00030-2018; 10.1183/23120541.00030-2018 Year: 2018
COVID-19 risk and outcomes in adult asthmatics treated with biologics or systemic corticosteroids: nationwide real-world evidence. Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
Evaluation of cardiovascular risk in a lung cancer screening cohort: what value does it bring? Source: Breathe, 16 (4) 200204; 10.1183/20734735.0204-2020 Year: 2020
Preliminary results of the impact of a French randomized feasibility trial of lung cancer screening on the quality of life, risk perception and smoking status: étude Dépiscan Source: Eur Respir J 2005; 26: Suppl. 49, 486s Year: 2005
Use of inhaled corticosteroids and the risk of osteoporosis: an international cohort study Source: International Congress 2018 – Epidemiology of asthma, COPD and factors that associate with lung function Year: 2018
New evidence on the chemoprevention of inhaled steroids and the risk of lung cancer in COPD Source: Eur Respir J, 53 (6) 1900717; 10.1183/13993003.00717-2019 Year: 2019
Overuse of short-acting ß2 -agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme Source: Eur Respir J, 55 (4) 1901872; 10.1183/13993003.01872-2019 Year: 2020
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study Source: Eur Respir J, 53 (6) 1801257; 10.1183/13993003.01257-2018 Year: 2019
The effect of smoking on the treatment outcome in patients with pulmonary tuberculosis: A prospective cohort study Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011
Comparison of risk prediction scores for venous thromboembolism in lung cancer patients: a retrospective cohort study Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019
Determinants of physical activity in individuals with lung cancer who has received chemotherapy: pilot study Source: International Congress 2017 – Assessing functional outcomes in respiratory physiotherapy Year: 2017
Use of NSAIDS compared to paracetamol as potential risk factors for asthma Source: Annual Congress 2010 - Paediatric respiratory epidemiology: early origins of childhood asthma Year: 2010
A case-control study of environmental risk factors of lung cancer Source: Eur Respir J 2007; 30: Suppl. 51, 425s Year: 2007
Montelukast and the risk of major adverse cardiovascular events – a Danish population-based case-control study Source: International Congress 2018 – Epidemiology of asthma, COPD and factors that associate with lung function Year: 2018
The impact of perceived risk, screening eligibility and worry on preference for lung cancer screening: a cross-sectional survey Source: ERJ Open Res, 6 (1) 00158-2019; 10.1183/23120541.00158-2019 Year: 2020
Interstital lung disease rates and risk factors in a UK lung cancer screening trial Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018
Prolonged anticoagulation in VTE with direct oral anticoagulants: towards an individual analysis of net clinical benefit? Source: Eur Respir J 2016; 48: 1268-1270 Year: 2016
How does current knowledge on primarily hereditary risk factors for asthma and other lung diseases improve prevention, treatment and prognosis? Source: Annual Congress 2012 - Genetics and genomics in asthma and COPD: prediction and personalised medicine Year: 2012